Oklo is designing and developing small nuclear reactors. After a strong run in 2025, the company's stock looks expensive.

"Healthy economic and revenue growth, continued profit strength among the largest US stocks, and an emerging productivity ...

The clinical-stage biotech could see its shares plummet should there be any clinical setback.

Expectations from the budget are limited as it often excites markets but rarely delivers major changes, with taxation and ...

However, historical headwinds are mounting for Wall Street, with several hot trends at risk of losing their luster.

High-growth companies must continue to innovate if they want to outperform the stock market, and prediction markets are ...

The stock market is at highs with JPMorgan, Goldman, Taiwan Semi and Delta earnings due. Two huge conferences, inflation data ...

Baird analyst Ben Kallo cut his rating on GE Vernova stock to Hold from Buy. He slashed his price target by $167 to $649 a ...

Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...

I think Broadcom has a great chance to outperform the market in 2026 and is well worth buying. But why is Broadcom a top ...

CoreWeave grows amid $18B debt, negative FCF, and timing gaps between infrastructure and cash generation. Check out why CRWV ...